Table 2.
Treatment characteristics for group
| Group | Values, n (%) |
|---|---|
| A | |
| Gemcitabine | 69 (53.5) |
| FOLFIRINOX | 29 (22.5) |
| Capecitabine + gemcitabine | 19 (14.7) |
| Nab-paclitaxel + gemcitabine | 5 (3.9) |
| Capecitabine | 5 (3.9) |
| Gem + paclitaxel | 1 (0.8) |
| FOLFOX | 1 (0.8) |
| Missing | 1 (0.8) |
| Total patients, n | 130 |
| B | |
| Nab-paclitaxel + gemcitabine | 139 (54.7) |
| FOLFIRINOX | 69 (27.2) |
| Gemcitabine | 30 (11.8) |
| PAXG | 5 (2.0) |
| PEXG | 3 (1.2) |
| GemOx | 2 (0.8) |
| Capecitabine/5-FU | 2 (0.8) |
| Gemcitabine + irinotecan | 1 (0.4) |
| Gemcitabine + capecitabine | 1 (0.4) |
| Irinotecan + oxaliplatin | 1 (0.4) |
| Gemcitabine + anetumab ravtansine | 1 (0.4) |
| Total patients, n | 254 |
| C | |
| Nab-paclitaxel + gemcitabine | 316 (70.5) |
| Gemcitabine | 71 (15.8) |
| FOLFIRINOX | 37 (8.3) |
| GemOx | 5 (1.1) |
| CAPOX | 2 (0.4) |
| PAXG | 2 (0.4) |
| 5-FU | 2 (0.4) |
| Nab-paclitaxel + gemcitabine + LY3200882 | 2 (0.4) |
| GemOx + olaparib | 2 (0.4) |
| Gemcitabine + anetumab ravtansine | 2 (0.4) |
| PEXG | 1 (0.2) |
| Nab-paclitaxel + gemcitabine + BBI-608 | 1 (0.2) |
| Irinotecan + nab-paclitaxel + gemcitabine | 1 (0.2) |
| FOLFIRINOX → olaparib | 1 (0.2) |
| Gem + cisplatin | 1 (0.2) |
| FOLFOX | 1 (0.2) |
| IRINOX | 1 (0.2) |
| Missing | 1 (0.2) |
| Total patients, n | 449 |
5-FU, fluorouracil; Gem, gemcitabine.